Literature DB >> 20043874

Sclerostin binds and regulates the activity of cysteine-rich protein 61.

Theodore A Craig1, Resham Bhattacharya, Debabrata Mukhopadhyay, Rajiv Kumar.   

Abstract

Sclerostin, a secreted glycoprotein, regulates osteoblast function. Using yeast two-hybrid and direct protein interaction analyses, we demonstrate that sclerostin binds the Wnt-modulating and Wnt-modulated, extracellular matrix protein, cysteine-rich protein 61 (Cyr61, CCN1), which regulates mesenchymal stem cell proliferation and differentiation, osteoblast and osteoclast function, and angiogenesis. Sclerostin was shown to inhibit Cyr61-mediated fibroblast attachment, and Cyr61 together with sclerostin increases vascular endothelial cell migration and increases osteoblast cell division. The data show that sclerostin binds to and influences the activity of Cyr61. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20043874      PMCID: PMC2821021          DOI: 10.1016/j.bbrc.2009.12.143

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13)

Authors:  M L Johnson; G Gong; W Kimberling; S M Reckér; D B Kimmel; R B Recker
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Authors:  Xiaofeng Li; Yazhou Zhang; Heeseog Kang; Wenzhong Liu; Peng Liu; Jianghong Zhang; Stephen E Harris; Dianqing Wu
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

3.  LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.

Authors:  Mikhail V Semenov; Xi He
Journal:  J Biol Chem       Date:  2006-10-19       Impact factor: 5.157

4.  Expression and regulation of CCN genes in murine osteoblasts.

Authors:  Muriel S Parisi; Elizabetta Gazzerro; Sheila Rydziel; Ernesto Canalis
Journal:  Bone       Date:  2005-11-28       Impact factor: 4.398

5.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

6.  Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting.

Authors:  Resham Bhattacharya; Junhye Kwon; Xiujuan Li; Enfeng Wang; Sujata Patra; John Paul Bida; Zeljko Bajzer; Lena Claesson-Welsh; Debabrata Mukhopadhyay
Journal:  J Cell Sci       Date:  2009-04-01       Impact factor: 5.285

7.  The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.

Authors:  Julie C Crockett; Norbert Schütze; Denise Tosh; Susanne Jatzke; Angela Duthie; Franz Jakob; Michael J Rogers
Journal:  Endocrinology       Date:  2007-09-06       Impact factor: 4.736

8.  Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.

Authors:  David G Winkler; Changpu Yu; James C Geoghegan; Ethan W Ojala; John E Skonier; Diana Shpektor; May K Sutherland; John A Latham
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

9.  The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Authors:  Wendy Balemans; Elke Piters; Erna Cleiren; Minrong Ai; Liesbeth Van Wesenbeeck; Matthew L Warman; Wim Van Hul
Journal:  Calcif Tissue Int       Date:  2008-06       Impact factor: 4.333

10.  Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.

Authors:  Rutger L van Bezooijen; Bernard A J Roelen; Annemieke Visser; Lianne van der Wee-Pals; Edwin de Wilt; Marcel Karperien; Herman Hamersma; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik
Journal:  J Exp Med       Date:  2004-03-15       Impact factor: 14.307

View more
  17 in total

1.  Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.

Authors:  Gill Holdsworth; Patrick Slocombe; Carl Doyle; Bernadette Sweeney; Vaclav Veverka; Kelly Le Riche; Richard J Franklin; Joanne Compson; Daniel Brookings; James Turner; Jeffery Kennedy; Rachael Garlish; Jiye Shi; Laura Newnham; David McMillan; Mariusz Muzylak; Mark D Carr; Alistair J Henry; Thomas Ceska; Martyn K Robinson
Journal:  J Biol Chem       Date:  2012-06-13       Impact factor: 5.157

2.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

3.  CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway.

Authors:  Jen-Liang Su; Jean Chiou; Chih-Hsin Tang; Ming Zhao; Chun-Hao Tsai; Pai-Sheng Chen; Yi-Wen Chang; Ming-Hsien Chien; Chu-Ying Peng; Michael Hsiao; Ming-Liang Kuo; Men-Luh Yen
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

4.  Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.

Authors:  Zachary C Ryan; Theodore A Craig; Jeffrey L Salisbury; Lomeli R Carpio; Meghan McGee-Lawrence; Jennifer J Westendorf; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2014-04-26       Impact factor: 3.575

5.  The sclerostin-bone protein interactome.

Authors:  Hemamalini Devarajan-Ketha; Theodore A Craig; Benjamin J Madden; H Robert Bergen; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2011-12-22       Impact factor: 3.575

6.  Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.

Authors:  Alexander G Robling; Rajendra Kedlaya; Shana N Ellis; Paul J Childress; Joseph P Bidwell; Teresita Bellido; Charles H Turner
Journal:  Endocrinology       Date:  2011-06-07       Impact factor: 4.736

7.  Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.

Authors:  Melissa McNulty; Ravinder J Singh; Xujian Li; Eric J Bergstralh; Rajiv Kumar
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

8.  Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin.

Authors:  Theodore A Craig; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2010-10-14       Impact factor: 3.575

9.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.

Authors:  Zachary C Ryan; Hemamalini Ketha; Melissa S McNulty; Meghan McGee-Lawrence; Theodore A Craig; Joseph P Grande; Jennifer J Westendorf; Ravinder J Singh; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

10.  Sclerostin as a new key player in arteriovenous fistula calcification.

Authors:  M Balcı; A Kırkpantur; A Turkvatan; S Mandıroglu; E Ozturk; B Afsar
Journal:  Herz       Date:  2013-10-19       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.